Cellusion
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing iPSC-derived corneal endothelial cell injection therapy to address the global shortage of donor corneas for transplants.
Ophthalmology
Technology Platform
Differentiation of induced pluripotent stem cells (iPSCs) into mass-producible, allogeneic corneal endothelial cell substitutes (CECSi) for cell injection therapy.
Opportunities
Addressing a massive unmet need with over 10 million patients awaiting corneal transplants globally; potential for geographic expansion if the scalable, off-the-shelf product gains approval.
Risk Factors
Clinical risks inherent to novel iPSC-derived cell therapies, including safety, efficacy, and potential immunogenicity; regulatory hurdles for first-in-class products; and future competition.
Competitive Landscape
Competes against traditional donor cornea transplants and other developing cell-based therapies; key differentiation is the scalable iPSC platform and less invasive injection procedure designed for wider physician adoption.